Cboe UK • CHF Kuros Biosciences AG (KURNZ.XC) Follow Compare 23.00 +3.44 (+17.59%) As of 3:39 PM GMT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for KURNZ.XC 1D 5D -19.01% 1M -2.95% 6M 189.31% YTD 574.49% 1Y 476.44% 2Y 1,403.27% 5Y 210.81% All -13.41% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: KURNZ.XC View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Kuros Biosciences Expands into Extremities Markets Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024 Kuros Biosciences Reports First Half of 2024 Results Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales Annual General Meeting of Kuros Biosciences Approves All Resolutions Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023 Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA